tbuckley/cabot-search huggingface dataset:
Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers
Authors: Carlotta Costa, Hiromichi Ebi, Anthony C. Faber, Madhuri Nishtala, Youngchul Song, Cyril H. Benes, Jeffrey A. Engelman
Journal: Cancer Research (2014)

Abstract The phosphatidylinositol 3-kinase (PI3K) family of lipid kinases plays a prominent role in the growth and survival of several types of cancer, including breast cancers where the PI3K pathway is altered in up to 70% of cases. Due to the technical challenges of measuring the PI3K product, PIP3 directly, the phosphorylation of the downstream effector AKT has historically been used to indirectly assess the activity of class I PI3K. While this approach has proven to be rather useful, it is based on the assumption that this readout is proportional to the levels of PIP3, which is likely to apply only to a limited range of activation levels and within specific contexts. Indeed, evaluation of the efficacy of PI3K inhibitors with such indirect measurements may approximate and oversimplify the complex transduction mechanism of PI3K. During time course experiments using the p110A selective inhibitor, BYL719, we observed that both PIP3 and p-AKT levels were similarly restored after 24 hours in HER2 amplified breast cancer cells, while the rebound of p-AKT was minimal and did not correlate with increased PIP3 levels in PIK3CA mutant breast cancer models. Both p110B inhibition and p110B depletion were effective in blocking the PIP3 rebound observed. Consistent with this, the combination of p110A and p110B inhibitors decreased cell growth and induced a better apoptotic response compared to BYL719 alone. We further demonstrated that only the combination of p110A and p110B inhibitors induced tumor regression. Importantly, PIP3 levels correlated with efficacy more reliably than p-AKT in a PIK3CA mutant model in vivo. These data suggest that measurement of PIP3 levels following treatment may serve as a more effective biomarker than p-AKT levels to predict response to PI3K inhibitors within this subset of breast cancers. Citation Format: Carlotta Costa, Hiromichi Ebi, Anthony C. Faber, Madhuri Nishtala, Youngchul Song, Cyril H. Benes, Jeffrey A. Engelman. Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2619. doi:10.1158/1538-7445.AM2014-2619
CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex
Authors: Greg C. A. Elson, Eric Lelièvre, Catherine Guillet, Sylvie Chevalier, Hélène Plun-Favreau, Josy Froger, Isabelle Suard, Amélie Benoit de Coignac, Yves Delneste, Jean-Yves Bonnefoy, Jean-François Gauchat, Hugues Gascan
Journal: Nature Neuroscience (2000)
Abstract P5-18-02: Trastuzumab interruption for treatment-induced cardiotoxicity in HER2 positive early breast cancer
Authors: Anthony F Yu, Nandini U Yadav, Betty Y Lung, Anne A Eaton, Howard T Thaler, Clifford A Hudis, Chau T Dang, Richard M Steingart
Journal: Cancer Research (2015)

Abstract Background Trastuzumab (H) improves outcomes among patients with HER2-positive breast cancer but is associated with a risk of treatment-induced cardiotoxicity (TIC), especially when administered after an anthracycline (A). H interruption is recommended for significant asymptomatic or symptomatic declines in left ventricular ejection fraction (LVEF). It is unclear how frequently TIC leads to H interruption, and the subsequent management is variable in clinical practice. Methods Patients (pts) with HER2-postive early breast cancer receiving adjuvant H with chemotherapy between January 2005 and October 2010 were studied (n=608). Tumor characteristics, chemotherapy regimen, cardiac risk factors, LVEF (at baseline and during treatment), and treatment interruption were obtained from the medical record. We evaluated the incidence, time of occurrence, management, and associated risk factors of H interruption due to TIC. Results Median age was 51 years (range 26-81); 488 (80%) pts had A prior to H administration. H was interrupted in 108 (18%) pts. Cumulative dose of H was lower among pts in the interrupted group (median 86 vs. 108 mg/kg, p &amp;lt; 0.0001). The most common reason for interruption was TIC (66 of 108 pts): 20 (30%) had symptomatic congestive heart failure and 46 (70%) had asymptomatic decline in LVEF. Of the 66 pts, 55 (83%) were referred to a cardiologist and 36 (55%) were prescribed a new cardiac medication. The mean LVEF at baseline, at time of cardiotoxicity diagnosis, and at follow-up after interruption of H was 63%, 45%, and 55%, respectively. Pts with H interruption for TIC were older (54 vs. 50 years, p=0.014) with lower LVEF before A (63 vs. 67%, p&amp;lt;0.0001) and before H therapy (62% vs. 67%, p&amp;lt;0.0001), compared to those with continuous H treatment. Thirty-three of 66 pts were re-treated with H, and 5 pts had a significant recurrent decline in LVEF. Conclusion At our institution, interruption of H therapy is common and most often due to TIC, from both A and H, with the majority of pts receiving A prior to H. Risk factors associated with H interruption were older age and lower LVEF prior to A and H administration. Cardiac dysfunction improved after interruption of treatment but did not fully recover to baseline. Strategies to prevent cardiotoxicity and minimize H treatment interruption should be investigated to prevent persistent LV dysfunction in affected pts. Citation Format: Anthony F Yu, Nandini U Yadav, Betty Y Lung, Anne A Eaton, Howard T Thaler, Clifford A Hudis, Chau T Dang, Richard M Steingart. Trastuzumab interruption for treatment-induced cardiotoxicity in HER2 positive early breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-18-02.
TREATMENT OF TWO PATIENTS WITH HEPATO-RENAL SYNDROME AND ACUTE RENAL FAILURE BY EXSANGUINOTRANSFUSION
Authors: I SNAPPER, L E SCHAEFER
Journal: Annals of Internal Medicine (1951)

Excerpt After exsanguinotransfusion had been tried and abandoned during the 17th century it was not used again until recently, when total replacement of blood was reintroduced by American clinician...
mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity
Authors: Gal Cafri, Adi Sharbi-Yunger, Esther Tzehoval, Zoya Alteber, Tamar Gross, Ezra Vadai, Alon Margalit, Gideon Gross, Lea Eisenbach
Journal: Molecular Therapy (2015)

Recently, we have developed a novel genetic platform for improving dendritic cell (DC) induction of peptide-specific CD8 T cells, based on membrane-anchored β2-microglobulin (β2m) linked to a selected antigenic peptide at its N-terminus and to the cytosolic domain of toll-like receptor (TLR)4 C-terminally. In vitro transcribed mRNA transfection of antigen presenting cells resulted in polypeptides that efficiently coupled peptide presentation to cellular activation. In the present study, we evaluated the immunogenicity of such constructs in mRNA-transfected immature murine bone marrow-derived DCs. We show that the encoded peptide β2m-TLR4 products were expressed at the cell surface up to 72 hours and stimulated the maturation of DCs. In vivo, these DCs prompted efficient peptide-specific T-cell activation and target cell killing which were superior to those induced by peptide-loaded, LPS-stimulated DCs. This superiority was also evident in the ability to protect mice from tumor progression following the administration of B16F10.9 melanoma cells and to inhibit the development of pre-established B16F10.9 tumors. Our results provide evidence that the products of two recombinant genes encoding for peptide-hβ2m-TLR4 and peptide-hβ2m-K(b) expressed from exogenous mRNA can cooperate to couple Major Histocompatibility Complex (MHC-I) peptide presentation to TLR-mediated signaling, offering a safe, economical and highly versatile genetic platform for a novel category of CTL-inducing vaccines.
STUDIES ON THE BINDING OF PROTEIN BY NICKEL..
Authors: D W. K. COTTON
Journal: British Journal of Dermatology (1964)

Journal Article STUDIES ON THE BINDING OF PROTEIN BY NICKEL.: WITH SPECIAL REFERENCES TO ITS ROLE IN NICKEL SENSITIVITY Get access D W. K. COTTON D W. K. COTTON The Institute of Dermatology, St. John's Hospital for Diseases of the Skin, Homerton Grove, London, E.9 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 76, Issue 3, 1 March 1964, Pages 99–109, https://doi.org/10.1111/j.1365-2133.1964.tb14487.x Published: 01 March 1964
Successful Discontinuation of Eltrombopag after Complete Remission in Patients with Primary Immune Thrombocytopenia
Authors: Tomás José González-López, Cristina Pascual, María Teresa Álvarez-Román, Fernando Fernández-Fuertes, Blanca Sánchez-González, Isabel Caparrós, Isidro Jarque, María Eva Mingot, José Ángel Hernández-Rivas, Mónica Martín-Salces, Laura Solán, Paola Beneit, Reyes Jiménez, Silvia Bernat, Marcio M Andrade, Montserrat Cortés, Maria José Cortti, Susana Pérez-Crespo, Marta Gómez-Núñez, Pavel E. Olivera, Gloria Pérez-Rus, Violeta Martínez-Robles, Rafael Alonso, Angeles Fernández-Rodríguez, María Carmen Arratibel, María Perera, Carmen Fernández-Miñano, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Isabel Gutierrez-Jomarrón, Inés Valcarce, Erik de Cabo, Adriana Sainz, Rosa Fisac, Carlos Aguilar, María Paz Martínez-Badas, María Jesús Peñarrubia, Javier Garcia-Frade, María Calbacho, Carmen de Cos, Manuel González-Silva, Erika Coria, Arancha Alonso, Alberto Casaus, Armando Luaña, Pilar Galán, Cristina Fernández-Canal, José Ramón González-Porras
Journal: Blood (2014)
How to drive away teenagers
Authors: Mary Selby
Journal: BMJ (1999)

as a function of both the point estimate itself and the sample size.Most statistical packages will generate exact binomial confidence intervals.Approximate confidence intervals can easily be calculated by using the formula for the SE of a proportion ('pq/n), which is based on a binomial approximation to the normal distribution and can be used to calculate 95% confidence intervals for sensitivity and specificity (for instance, p±1.96'pq/n,where p represents either sensitivity or specificity, q = 1p, n is the sample size, and where n × p is > 10).To enhance the quality of information on diagnostic tests made available to clinicians we recommend that 95% confidence intervals are supplied with estimates of diagnostic accuracy.Referees and journal editors should enforce this requirement in the same way as they routinely do for other descriptive or comparative estimates.
Models of cardiac rehabilitation
Authors: D P de Bono
Journal: BMJ (1998)

Papers p 1354 

The survey by Lewin and colleagues of cardiac rehabilitation in the United Kingdom paints a picture of services predominantly provided by nurses and physiotherapists, with little formal input from physicians or psychologists, and a need both for more extensive use of validated methods of assessment and of formal audit (p 1354).1 Clinicians will bristle (I bristled) at the insinuation that they are not involved in rehabilitation. Cardiac and general medical outpatients clinics are full, we say, of patients being followed up after myocardial infarction or cardiac surgery. In theory (our theory) this should run parallel with and form part of the formal rehabilitation process. In practice, it often does not. Ten minutes of structured consultant time in the context of …
Interferon-γ enhances superoxide production in human mesangial cells via the JAK–STAT pathway
Authors: K. Moriwaki, H. Kiyomoto, H. Hitomi, G. Ihara, K. Kaifu, K. Matsubara, T. Hara, N. Kondo, K. Ohmori, A. Nishiyama, T. Fukui, M. Kohno
Journal: Kidney International (2006)
Clinical Factors and Recurrent Venous Thrombotic Events—Reply
Authors: Suzanne C. Cannegieter, Frits R. Rosendaal
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-377 Multimodality intravascular imaging assessment of plaque erosion vs plaque rupture in patients with acute coronary syndrome
Authors: Hoyoun Won, Sang Wook Kim, Gary S. Mintz, Young Joon Hong, Sung Yun Lee, Ki Seok Kim, Young Kim, Jee Eun Kwon, Seonghyeop Hyeon, Seung Yong Shin, Kwang Je Lee, Wang Soo Lee, Tae Ho Kim, Chee Jeong Kim
Journal: Journal of the American College of Cardiology (2014)
Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes
Authors: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, Rafael Sanchez-Salas, Marc Galiano, Francois Rozet, Dominique Prapotnich, Nathalie Cathala, Annick Mombet, Xavier Cathelineau
Journal: European Urology (2015)
Abstract 11536: Real-Time Hemodynamic and Volumetric Monitoring in Patients With Takotsubo Cardiomyopathy After Subarachnoid Hemorrhage
Authors: Tatsushi Mutoh, Tatsuya Ishikawa, Yasuyuki Taki, Akifumi Suzuki
Journal: Circulation (2014)

Introduction:  Takotsubo cardiomyopathy (TCM) is a life-threatening systemic consequence early after subarachnoid hemorrhage (SAH), but precise hemodynamics and related outcome have not been studied.   Hypothesis:  The purpose of this study was to investigate the TCM-induced cardiac function by transpulmonary thermodilution and its impact on clinical outcome of SAH.   Methods:  We analyzed retrospectively 46 consecutive postoperative SAH patients who developed TCM. Patients were divided into two groups of LVEF    Results:  Transpulmonary thermodilution-derived CFI was correlated significantly with echocardiographic left ventricular ejection fraction (LVEF) ( r  = 0.82,  P   P  P   –1  had a sensitivity of 82% and specificity of 84% for detecting LVEF  -1  was associated with delayed cerebral ischemia (DCI) (odds ratio [OR], 2.14; 95% confidence interval [CI], 1.33-2.86;  P  = 0.004) and poor 3-month functional outcome on modified Rankin Scale of 4-6 (OR, 1.87; 95% CI, 1.06-3.29;  P  = 0.02). An ELWI > 14 mL/kg after day 4 increased the risk of poor functional outcome at 3-month follow-up (OR, 2.10; 95% CI, 1.11-3.97;  P  = 0.04).   Conclusions:  Prolonged cardiac dysfunction and pulmonary edema increased the risk of DCI and poor 3-month functional outcome in patients with SAH suffering from TCM. Serial measurements of CFI and ELWI by transpulmonary thermodilution may provide an easy bedside method of detecting early changes of the cardiopulmonary function in directing proper post-SAH treatment.
825. Downstream Processing of Supercoiled Plasmid DNA
Authors: Lena M. Sandberg, Annika Andersson, Jozsef Vasi, Marianne Sparrman, Emma Håkansson, Per Nilsson, Raf Lemmens
Journal: Molecular Therapy (2004)

The production of highly purified supercoiled plasmid DNA in large quantities for gene therapy is a prerequisit for the success of plasmid DNA as a therapeutic. The shift from small-scale plasmid production (for cell transfections at the benchtop level) to large-scale production for gene therapy and DNA vaccines poses new demands on the bacterial fermentation, bacterial lysate processing and the final purification of plasmid DNA. To meet these objectives a cost-effective and generic production process for plasmid DNA was developed.
Drug Abuse “Propaganda”
Authors: Mike Mitka
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of Th1/Th2 cytokines as a rapid diagnostic tool for severe infection in paediatric haematology/oncology patients by the use of cytometric bead array technology
Authors: Y. Tang, C. Liao, X. Xu, H. Song, S. Shi, S. Yang, F. Zhao, W. Xu, X. Chen, J. Mao, L. Zhang, B. Pan
Journal: Clinical Microbiology and Infection (2011)
Breast Carcinoma Metastatic to the Iris
Authors: J A Shields, J L Tovilla-Canales, C L Shields, G V Mercado, H Ehya
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Women's Sexual Experience. Explorations of the Dark Continent.
Authors: Martha Kirkpatrick
Journal: Annals of Internal Medicine (1982)

I * The General Condition.- 1 * Women's Sexual Response.- 2 * The Sexual Experience of Afro-American Women: A Middle-Income Sample.- Discussion * Further Thoughts on a Group Discussion by Black Women about Sexuality.- 3 * Sexual Consequences of Acculturation of American Indian Women.- Discussion * Myths in the Midst of Missing Data.- 4 * Sex and Sexuality: Women at Midlife.- Discussion * Midlife Women: Lessons for Sex Therapy.- 5 * In Praise of Older Women.- Discussion * Aging and Female Sexuality.- II * Special Circumstances.- 6 * The Cradle of Sexual Politics: Incest.- 7 * Beyond Belief: The Reluctant Discovery of Incest.- 8 * Effects of Teenage Motherhood.- 9 * Does Motherhood Mean Maturity?.- Discussion * Some Developmental Aspects of Adolescent Mothers.- 10 * Female Sexuality and Pregnancy.- Discussion * The Developmental Crisis of Pregnancy.- 11 * Voluntary Childlessness.- Discussion * Voluntary Sterilization in Childless Women.- 12 * Women in Swinging: America's Amazon Society?.- Discussion * Extramarital Sex: A Multifaceted Experience.- 13 * Wife Beating: A Product of Sociosexual Development.- Discussion * Psychoanalytic Reflections on the Beaten Wife Syndrome.- 14 * The Prostitute as a Victim.- Discussion * Legal Victim or Social Victim?.- 15 * Women-Victims of the VD Rip-Off.- Discussion * Prophylaxis of Sexually Transmitted Diseases: An Overview.
Abstract P307: The Incremental Value of Fourteen Novel Biomarkers for the Prediction of Cardiovascular Risk in Patients with Type 2 Diabetes
Authors: Joep van der Leeuw, Joline W Beulens, Linda M Peelen, Susan van Dieren, Stephan J Bakker, Ineke J Riphagen, Casper G Schalkwijk, Yolanda van der Graaf, Frank L Visseren, Yvonne T van der Schouw
Journal: Circulation (2015)

Background:  Type 2 diabetes patients are at a two to four fold increased risk of cardiovascular disease (CVD). Treatments guidelines recommend risk scores to estimate CVD risk of type 2 diabetes patients. However, such risk scores only have moderate discriminative ability to predict CVD.   Aim:  This study aimed to evaluate whether fourteen novel biomarkers representing several pathophysiological pathways could improve CVD prediction in patients with type 2 diabetes beyond traditional risk factors.   Methods:  We prospectively followed 1002 patients with type 2 diabetes from the Second Manifestations of ARTerial disease (SMART) study. The associations of fourteen biomarkers (adiponectin, N-terminal prohormone of B-type natriuretic peptide (NT-proBNP), matrix metalloproteinases (MMP) 1, 3 and 9, basic fibroblast growth factor, placental growth factor, soluble fms-like tyrosine kinase, vascular endothelial growth factor, osteocalcin, osteonectin, osteopontin, heart-type and epidermal-type fatty acid binding protein) with CVD risk were evaluated using Cox proportional hazards analyses adjusting for predictors from the UKPDS risk score, history of CVD and albuminuria. Incremental predictive performance was assessed by the c-statistic, the continuous net reclassification index (cNRI) and the categorical NRI.   Results:  During a median follow-up of 9.2 years, 248 major cardiovascular events occurred.  NT-proBNP, osteopontin and MMP-3 were independently associated with an increased CVD risk and improved predictive performance. The base model showed a c-statistic of 0.70 (0.67-0.74). Addition of NT-proBNP resulted in a c-statistic increase of 0.02 [95%CI 0.00-0.04] and a cNRI of 0.27 [95% CI 0.10-0.45]. Addition of osteopontin resulted in a c-statistic increase of 0. 01[95%CI 0.00-0.03] and a cNRI of 0.33 [95%CI 0.17-0.48]. Addition of MMP-3 resulted in a c-statistic increase of 0.01 [95%CI 0.01-0.03] and a cNRI of 0.25 [95%CI 0.08-0.42]. Addition of the other biomarkers did not result in significant changes of the c-statistic or cNRI. The categorical NRI was 0. 08[95%CI-0.01-0.17] for NT-proBNP, 0.05 [95%CI-0.02-013] for osteopontin and 0. 05[95%CI -0.03-0.13] for MMP-3. Replication of these findings in two independent cohorts is ongoing.   Conclusions:  Of fourteen evaluated biomarkers, NT-proBNP, osteopontin and MMP-3 improved the accuracy of CVD risk prediction in patients with type 2 diabetes on top of traditional risk factors. Future research should evaluate the economic costs and clinical benefits of routine measurement of these biomarkers.